Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their product pipeline. They acknowledged challenges but emphasized their commitment to future growth.
Management highlighted ongoing commitment to pipeline development.
They expressed confidence in long-term growth despite current challenges.
Rhythm Pharmaceuticals reported a loss per share of $0.60, which was in line with expectations as no consensus was available. Despite the loss, the stock rose by 12.83%, likely driven by positive sentiment around their product pipeline and management's commitment to growth. Investors may be optimistic about future developments even in the absence of revenue data.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AGILENT TECHNOLOGIES
May 14, 2018